Estructura del sistema de cría y variabilidad genética del núcleo de control cárnico del esquema de selección de la raza retinta

En el presente trabajo se ha abordado el análisis del flujo genético, la estructura poblacional y la variabilidad genética del Núcleo de Control Cárnico (NCC) del Esquema de Selección de la Raza Retinta desde su inicio hasta la actualidad. El Núcleo de Control Cárnico del Esquema de Selección de la Raza Retinta cuenta actualmente con 40499 animales controlados. De éstos, 19756 pertenecen a alguna de las 64 ganaderías actualmente inscritas en dicho Esquema. Estas últimas son las que nos ocupan en el estudio. En primer lugar se ha llevado a cabo un estudio de la contribución de las ganaderías del NCC a la población en control a partir de la aportación de animales controlados y de reproductores. Esto ha permitido conocer las ganaderías que pueden considerarse de élite y el flujo existente dentro del núcleo. Para determinar el nivel de variabilidad existente en las ganaderías del NCC se ha evaluado el porcentaje de consanguinidad y el coeficiente de parentesco. Por último se ha estimado la distancia genética entre las ganaderías del Núcleo, teniendo en cuenta el grado de parentesco genealógico medio entre los reproductores de cada ganadería

Detección de single nucleotide polymorphisms en genes relacionados con la terneza de la carne (capn1 y cast) en las razas bovinas autóctonas españolas

Ministerio de Agricultura, Pesca y Alimentació

Non-Invasive Electrophysiological Mapping Entropy Predicts Atrial Fibrillation Ablation Efficacy Better Than Clinical Characteristics

[EN] Success rate of atrial fibrillation (AF) ablation remains far from satisfactory. In this study, a 6 months AF freedom predictive model based on Fuzzy Entropy of non-invasive body surface potential maps is compared with clinical predictors. The study included 29 patients referred for pulmonary vein isolated catheter ablation procedure. Non-invasive electrocardiographic mapping with 54 ECG electrodes was recorded for all patients during the ablation procedure. Six months follow up was used to evaluate the efficacy of the ablation procedure. Predictions based on non-invasive electrocardiographic mappings during adenosine infusion (accuracy: 90%, AUC: 0.93) showed a clear improvement over standard-of-care clinical parameter models (accuracy: 62.1%, AUC: 0. 54). Our results indicate that measurements of electrophysiological complexity of AF signals could improve the clinical practice by predicting the efficacy of AF ablation procedures.This work was supported by the Instituto de Salud Carlos III FEDER (DTS16/00160; PI16/01123; PI17/01059; PI17/01106; EIT-Health 19600 AFFINE)De La Nava, AS.; Fabregat, MC.; Rodrigo, M.; Hernández, I.; Liberos, A.; Fernández-Avilés, F.; Guillem Sánchez, MS.... (2019). Non-Invasive Electrophysiological Mapping Entropy Predicts Atrial Fibrillation Ablation Efficacy Better Than Clinical Characteristics. IEEE. 1-4. https://doi.org/10.22489/CinC.2019.299S1

[Real Avilés Club de Fútbol I] [Material gráfico]

Contiene fotografías pertenecientes al archivo fotográfico del diario "Región", publicadas entre 1964 y 1982Algunas fotos no indican autoría; el resto firmadas por Foto E. Gar (Oviedo), Foto Sierra (Oviedo), Reportajes Fotográficos Marcos (Avilés), Antonio Rodríguez Fernández (Carbayín, Siero), Foto Alsua (Avilés), Foto Álvaro (La Rocica, Avilés

Tissue engineering by decellularization and 3D bioprinting

Discarded human donor organs have been shown to provide decellularized extracellular matrix (dECM) scaffolds suitable for organ engineering. The quest for appropriate cell sources to satisfy the need of multiple cells types in order to fully repopulate human organ-derived dECM scaffolds has opened new venues for the use of human pluripotent stem cells (hPSCs) for recellularization. In addition, three-dimensional (3D) bioprinting techniques are advancing towards the fabrication of biomimetic cell-laden biomaterial constructs. Here, we review recent progress in decellularization/recellularization and 3D bioprinting technologies, aiming to fabricate autologous tissue grafts and organs with an impact in regenerative medicine

Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development

This work aims to review the role of endothelial dysfunction underlying the main complications appearing early after autologous and allogeneic hematopoietic cell transplantation (HCT). The endothelial damage as the pathophysiological substrate of sinusoidal obstruction syndrome (SOS) is well established. However, there is growing evidence of the involvement of endothelial dysfunction in other complications, such as acute graft-versus-host disease (aGVHD) and transplant-associated thrombotic microangiopathy (TA-TMAs). Moreover, HCT-related endotheliopathy is not only limited to the HCT setting, as there is increasing evidence of its implication in complications derived from other cellular therapies. We also review the incidence and the risk factors of the main HCT complications and the biological evidence of the endothelial involvement and other linked pathways in their development. In addition, we cover the state of the art regarding the potential use of the biomarkers of endotheliopathy in the prediction, the early diagnosis, and the follow-up of the HCT complications and summarize current knowledge points to the endothelium and the other linked pathways described as potential targets for the prevention and treatment of HCT-complications. Lastly, the endothelium-focused therapeutic strategies that are emerging and might have a potential impact on the survival and quality of life of post-HCT-patients are additionally reviewed.Copyright © 2022 Moreno-Castaño, Salas, Palomo, Martinez-Sanchez, Rovira, Fernández-Avilés, Martínez, Cid, Castro, Escolar, Carreras and Diaz-Ricart

Spanish Cell Therapy Network (TerCel) : 15 years of successful collaborative translational research

In the current article we summarize the 15-year experience of the Spanish Cell Therapy Network (TerCel), a successful collaborative public initiative funded by the Spanish government for the support of nationwide translational research in this important area. Thirty-two research groups organized in three programs devoted to cardiovascular, neurodegenerative and immune-inflammatory diseases, respectively, currently form the network. Each program has three working packages focused on basic science, pre-clinical studies and clinical application. TerCel has contributed during this period to boost the translational research in cell therapy in Spain, setting up a network of Good Manufacturing Practice-certified cell manufacturing facilities- and increasing the number of translational research projects, publications, patents and clinical trials of the participating groups, especially those in collaboration. TerCel pays particular attention to the public-private collaboration, which, for instance, has led to the development of the first allogeneic cell therapy product approved by the European Medicines Agency, Darvadstrocel. The current collaborative work is focused on the development of multicenter phase 2 and 3 trials that could translate these therapies to clinical practice for the benefit of patients

[Prieto] [Material gráfico]

Contiene fotografías pertenecientes al archivo fotográfico del diario "Región", publicadas entre 1969 y 1983Algunas fotos no indican autoría; el resto firmadas por Foto Sierra (Oviedo), Foto E. Gar (Oviedo), Reportajes Fotográficos Marcos (Avilés), Antonio Rodríguez Fernández (Carbayín, Siero